Eccogene raises funds for clinical-stage metabolic pipeline development

Preview

来源: Pharmaceutical Technology

Eccogene’s ECC5004 has been designed to treat obesity and type 2 diabetes. Credit: abolukbas / Shutterstock.com.

Clinical-stage biotechnology firm Eccogene has raised $25.23m (CNY180m) in a Series B financing round to support the development of its clinical-stage metabolic pipeline.

Co-led by Zhangjiang Healthcare Venture Capital and New Alliance Capital, the financing round has seen participation from existing investors Qingsong Capital, Delos Capital and Oriza Seed Capital.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsClinical Trials - The Expanding Landscape of Regenerative Medicine GlobalData

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - Trecondyv in Hematopoietic Stem Cell Transplantation GlobalData

View all

New investors Elikon Venture, YuFu Investment, Rockbleu Capital and Huajin Capital have also participated in the financing round.

Eccogene’s clinical pipeline includes a once daily, low-dose, small molecule GLP-1 receptor agonist (GLP-1RA), ECC5004, designed for type 2 diabetes (T2D) and obesity.

The therapy is being evaluated in a US Phase I clinical trial in T2D patients and healthy participants.

ECC4703 is a THRβ full agonist, now being assessed in a US Phase I trial in patients with elevated LDL and healthy participants. In preclinical trials, the therapy showed superiority over partial agonist MGL-3196 and robust efficacy in pre-clinical NASH [a form of non-alcoholic fatty liver disease that involves inflammation of the liver and liver damage, in addition to fat in the liver] and dyslipidemia models.

ECC0509 is a peripherally distributed SSAO/VAP-1 inhibitorSSAO/VAP-1 inhibitor that is nearing completion of a Phase I clinical trial.

Eccogene also intends to use the proceeds from the financing to further advance its preclinical programmes to treat metabolic and immunological diseases.

Eccogene CEO Jingye Zhou stated: “We are thrilled that the series B financing enables us to advance clinical trials of a potentially best-in-class small molecule GLP-1RA to treat obesity, diabetes and related complications, and to further develop several highly differentiated assets for metabolic and immunological diseases.

“This financing brings us a step closer to providing clinical benefits to hundreds of millions of patients affected by obesity, T2D and NASH globally.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。